Grufity logoGrufity logo

Neogen Corp Stock Research

NEOG

18.52USD+1.07(+6.13%)Market Closed

Market Summary

USD18.52+1.07
Market Closed
6.13%

NEOG Stock Price

NEOG RSI Chart

NEOG Valuation

Market Cap

4.0B

Price/Earnings (Trailing)

-246.65

Price/Sales (Trailing)

6.35

EV/EBITDA

91.26

Price/Free Cashflow

-679.89

NEOG Price/Sales (Trailing)

NEOG Profitability

EBT Margin

-0.30%

Return on Equity

-0.52%

Return on Assets

-0.36%

Free Cashflow Yield

-0.15%

NEOG Fundamentals

NEOG Revenue

Revenue (TTM)

630.7M

Revenue Y/Y

76.25%

Revenue Q/Q

73.81%

NEOG Earnings

Earnings (TTM)

-16.2M

Earnings Y/Y

-486.41%

Earnings Q/Q

-903.24%

Price Action

52 Week Range

10.4931.83
(Low)(High)

Last 7 days

1.7%

Last 30 days

0.9%

Last 90 days

21.6%

Trailing 12 Months

-39.9%

NEOG Financial Health

Current Ratio

4.22

NEOG Investor Care

Shares Dilution (1Y)

100.81%

Diluted EPS (TTM)

0.05

Peers (Alternatives to Neogen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.6B
31.5B
2.72% -13.99%
25.46
5.83
6.85% 12.06%
177.5B
43.7B
0.43% -13.32%
25.6
4.07
1.34% -1.95%
107.3B
30.8B
-1.78% -26.78%
26.38
3.49
-3.19% -17.38%
41.5B
3.4B
6.60% -8.59%
61.04
12.31
4.73% -8.83%
25.7B
2.9B
8.86% -15.64%
43.82
8.89
1.95% -11.47%
MID-CAP
10.6B
847.1M
7.86% 25.46%
-5.3K
12.54
13.32% -137.89%
5.7B
935.1M
12.97% 49.27%
202.4
6.08
119.91% 139.38%
4.0B
630.7M
0.87% -39.95%
-246.65
6.35
25.40% -128.45%
3.7B
-
4.25% -20.78%
3.27
1.42
- -
SMALL-CAP
1.5B
301.6M
2.29% 56.91%
-550.1
4.93
-3.75% -104.51%
1.2B
237.3M
8.94% -31.25%
-25.59
4.89
6.59% 84.02%
1.0B
257.3M
14.46% -29.40%
-50.89
3.93
1.41% -1632.49%
45.5M
7.9M
3.13% -64.81%
-1.47
5.78
23.02% -7.81%
766.7K
37.4M
-50.00% -99.61%
-0.01
0.02
-2.49% 10.49%

Financials for Neogen

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue18.7%631531527514503
Gross Profit21.2%297245243236232
Operating Expenses35.6%274202184175162
  S&GA Expenses17.3%10387.0085.0084.0081.00
  R&D Expenses14.3%20.0018.0017.0017.0017.00
EBITDA-37.9%43.0069.0084.0085.00-
EBITDA Margin-47.7%0.07*0.13*0.16*0.17*-
Earnings Before Taxes-104.2%-1.8845.0060.0061.0071.00
EBT Margin-103.5%0.00*0.08*0.11*0.12*-
Net Income-144.5%-16.2336.0048.0049.0057.00
Net Income Margin-137.5%-0.03*0.07*0.09*0.10*-
Free Cahsflow-119.2%-5.8931.0068.0070.00-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets366.9%4,563977993981968
  Current Assets5.8%643608627610611
    Cash Equivalents-6.6%10010744.0043.0051.00
  Inventory5.4%136129122113107
  Net PPE22.4%148121111105101
  Goodwill1415.3%2,122140143150143
Liabilities1456.5%1,45794.00106106101
  Current Liabilities127.7%15367.0078.0066.0063.00
    LT Debt, Non CurrentInfinity%924----
Shareholder's Equity251.5%3,106884887876865
  Retained Earnings-7.1%551593588573568
  Additional Paid-In Capital718.8%2,561313310308305
Accumulated Depreciation-105----
Shares Outstanding100.4%216108108108108
Float-4,325----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-119.2%-5.8931.0068.0070.0075.00
  Share Based Compensation12.1%8.007.007.007.007.00
Cashflow From Investing1348.2%14210.00-97.23-111-157
Cashflow From Financing-1271.8%-78.167.007.0019.0028.00

Risks for NEOG

What is the probability of a big loss on NEOG?

63.9%


Probability that Neogen stock will be more than 20% underwater in next one year

40.8%


Probability that Neogen stock will be more than 30% underwater in next one year.

33.9%


Probability that Neogen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NEOG drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Neogen was unfortunately bought at previous high price.

Drawdowns

Returns for NEOG

Cumulative Returns on NEOG

4.0%


10-Year Cumulative Returns

0.1%


7-Year Cumulative Returns

-11.2%


5-Year Cumulative Returns

-17.9%


3-Year Cumulative Returns

What are the long-term rolling returns for NEOG?

FIve years rolling returns for Neogen.

Annualized Returns

Which funds bought or sold NEOG recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
added
27.06
1,038,770
3,735,710
0.03%
2023-03-17
American Portfolios Advisors
reduced
-3.17
-22,975
29,421
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
86.34
2,339,510
4,606,510
-%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
reduced
-1.33
31,945
450,945
0.07%
2023-03-08
Capital Asset Advisory Services LLC
sold off
-100
-152,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-93.48
-6,000
-
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
reduced
-45.85
-3,431
4,569
-%
2023-02-28
Voya Investment Management LLC
reduced
-68.16
-2,268,590
1,206,410
-%
2023-02-27
Parallax Volatility Advisers, L.P.
reduced
-98.07
-116,502
2,498
-%
2023-02-24
NATIXIS
reduced
-79.47
-133,311
36,689
-%

1–10 of 46

Latest Funds Activity

Are funds buying NEOG calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own NEOG
No. of Funds

Neogen News

The DBT News

Neogen Corporation [NEOG] Revenue clocked in at $630.70 million ....

The DBT News,
11 hours ago

InvestorsObserver

Zacks Investment Research

InvestorsObserver

Investor's Business Daily

New Haven Register

Neogen: Fiscal Q3 Earnings Snapshot.

New Haven Register,
45 hours ago

Marketscreener.com

Investor's Business Daily

Schedule 13G FIlings of Neogen

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
susquehanna securities, llc
3.8%
8,291,607
SC 13G/A
Feb 14, 2023
norges bank
8.52%
18,422,570
SC 13G/A
Feb 09, 2023
vanguard group inc
8.82%
19,057,576
SC 13G/A
Feb 08, 2023
wasatch advisors inc
-
0
SC 13G/A
Jan 23, 2023
blackrock inc.
11.3%
24,460,988
SC 13G/A
Sep 16, 2022
susquehanna securities, llc
5.4%
11,733,386
SC 13G
Sep 09, 2022
wasatch advisors inc
-
0
SC 13G/A
Sep 01, 2022
norges bank
5.79%
6,248,066
SC 13G
Feb 14, 2022
brown capital management llc
11.04%
11,899,239
SC 13G/A
Feb 11, 2022
wasatch advisors inc
-
0
SC 13G

NEOG Fair Value

Neogen fair value in different scenarios

The table shows the Fair Value estimates for Neogen for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

7.53

-59.34%

8.51

-54.05%

10.79

-41.74%

12.88

-30.45%

14.49

-21.76%
Current Inflation

7.18

-61.23%

8.01

-56.75%

9.94

-46.33%

11.69

-36.88%

13.02

-29.70%
Very High Inflation

6.75

-63.55%

7.42

-59.94%

8.95

-51.67%

10.31

-44.33%

11.34

-38.77%

Historical Neogen Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Neogen

View All Filings
Date Filed Form Type Document
Mar 30, 2023
8-K
Current Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 08, 2023
SC 13G/A
Major Ownership Report
Jan 30, 2023
4
Insider Trading
Jan 23, 2023
SC 13G/A
Major Ownership Report
Jan 18, 2023
4
Insider Trading
Jan 09, 2023
10-Q
Quarterly Report
Jan 05, 2023
8-K
Current Report

Latest Insider Trading transactions for NEOG

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-26
BOEHM WILLIAM T
acquired
23,430
15.62
1,500
-
2023-01-26
BOEHM WILLIAM T
sold
-15,060
20.08
-750
-
2023-01-13
Jones Douglas Edward
bought
44,775
17.91
2,500
chief operating officer
2022-10-11
Quinlan Steven J.
bought
58,150
11.63
5,000
vp & cfo
2022-10-03
BOEHM WILLIAM T
bought
27,770
13.885
2,000
-
2022-09-28
ADENT JOHN EDWARD
bought
316,140
14.37
22,000
president & ceo
2022-09-28
Jones Douglas Edward
bought
100,170
14.31
7,000
chief operating officer
2022-08-16
Vetter Darci L
bought
24,013
21.83
1,100
-
2022-08-02
Green Ronald D
bought
33,750
22.5
1,500
-
2022-07-29
ADENT JOHN EDWARD
bought
403,725
23.07
17,500
president & ceo

1–10 of 50

John E. Adent
1840
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

NEOG Income Statement

2022-11-30
Consolidated Statements of Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Revenues    
Total Revenues$ 230,033$ 130,517$ 362,382$ 258,822
Cost of Revenues    
Total Cost of Revenues117,49469,923187,573138,220
Gross Margin112,53960,594174,809120,602
Operating Expenses    
Sales and marketing36,34821,18859,73141,743
General and administrative77,00122,605104,94535,988
Research and development6,8464,33211,7278,657
Total Operating Expenses120,19548,125176,40386,388
Operating Income (Loss)(7,656)12,469(1,594)34,214
Other Income (Expense)    
Interest income5532461,523455
Interest expense(20,545)(22)(20,547)(28)
Other income (expense)(6,443)235(6,814)14
Total Other Income (Expense)(26,435)459(25,838)441
Income (Loss) Before Taxes(34,091)12,928(27,432)34,655
Provision for Income Taxes7,7502,1009,2006,750
Net Income (Loss)$ (41,841)$ 10,828$ (36,632)$ 27,905
Net Income (Loss) Per Share    
Basic$ (0.19)$ 0.1$ (0.23)$ 0.26
Diluted$ (0.19)$ 0.1$ (0.23)$ 0.26
Weighted Average Shares Outstanding    
Basic216,134107,641161,690107,565
Diluted216,134108,122161,690108,099
Product Revenues    
Revenues    
Total Revenues$ 203,317$ 106,111$ 310,109$ 210,124
Cost of Revenues    
Total Cost of Revenues102,53056,374157,971111,100
Service Revenues    
Revenues    
Total Revenues26,71624,40652,27348,698
Cost of Revenues    
Total Cost of Revenues$ 14,964$ 13,549$ 29,602$ 27,120

NEOG Balance Sheet

2022-11-30
Consolidated Balance Sheets - USD ($)
Nov. 30, 2022
May 31, 2022
Current Assets  
Cash and cash equivalents$ 100,000,000$ 44,473,000
Marketable securities176,338,000336,578,000
Accounts receivable, net of allowance of $1,950 and $1,650 at November 30, 2022 and May 31, 2022, respectively142,711,00099,674,000
Inventories136,069,000122,313,000
Prepaid expenses and other current assets88,215,00023,760,000
Total Current Assets643,333,000626,798,000
Net Property and Equipment148,170,000110,584,000
Other Assets  
Right of use assets3,707,0003,184,000
Goodwill2,122,397,000142,704,000
Other non-amortizable intangible assets15,216,00015,397,000
Amortizable intangible and other assets, net of accumulated amortization of $78,046 and $55,416 at November 30, 2022 and May 31, 2022, respectively1,626,514,00092,106,000
Other non-current assets3,905,0002,156,000
Total Assets4,563,242,000992,929,000
Current Liabilities  
Accounts payable79,251,00034,614,000
Accrued compensation15,014,00011,123,000
Income tax payable9,049,0002,126,000
Accrued interest13,974,0000
Deferred revenue5,083,0005,460,000
Other accruals30,187,00024,521,000
Total Current Liabilities152,558,00077,844,000
Deferred Income Tax Liability364,252,00017,011,000
Non-current debt923,962,0000
Other non-current liabilities16,207,00010,700,000
Total Liabilities1,456,979,000105,555,000
Commitments and Contingencies (note 12)
Equity  
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding00
Common stock, $0.16 par value, 315,000,000 shares authorized, 216,154,283 and 107,801,094 shares issued and outstanding at November 30, 2022 and May 31, 2022, respectively34,584,00017,248,000
Additional paid-in capital2,560,898,000309,984,000
Accumulated other comprehensive loss(40,498,000)(27,769,000)
Retained earnings551,279,000587,911,000
Total Stockholders' Equity3,106,263,000887,374,000
Total Liabilities and Stockholders' Equity$ 4,563,242,000$ 992,929,000